Atlas Trials

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Clinical trial NCT06010212 · UNKNOWN

Trial details

NCT number
NCT06010212
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2023-08-25
Primary completion
2025-08-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.